[1]张一帆,李彪.钠/碘同向转运体在甲状腺癌131I治疗中的应用[J].国际放射医学核医学杂志,2004,28(6):249-252.
　ZHANG Yi-fan,LI Biao.Application of sodium/iodide symporter gene in thyroid cancer for radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):249-252.
点击复制

钠/碘同向转运体在甲状腺癌131I治疗中的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
28
期数:
2004年第6期
页码:
249-252
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Application of sodium/iodide symporter gene in thyroid cancer for radiotherapy
作者:
张一帆;  李彪
200025 上海, 上海第二医科大学附属瑞金医院核医学科
Author(s):
ZHANG Yi-fan;  LI Biao
Department of Nuclear Medicine, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China
关键词:
钠/碘同向转运体; 甲状腺癌; 放射性核素治疗; 基因治疗
Keywords:
sodium/iodine symporter; thyroid cancer; gene therapy; radiotherapy
分类号:
R817.4
摘要:
钠/碘同向转运体(Na+/I- symporter,NIS)是一种膜蛋白,介导甲状腺滤泡细胞的碘转运,在甲状腺癌的病理生理及131I治疗中起着重要的作用。多数研究表明,甲状腺癌的NIS mRNA及蛋白表达水平降低;维甲酸、去甲基化及组蛋白脱乙酰酶抑制剂可刺激失分化甲状腺癌细胞的NIS表达,为甲状腺癌131I的有效治疗进行了有益的探索。NIS基因的克隆和其特性的揭示为甲状腺癌的靶向基因放射治疗提供了可能。
Abstract:
As the thyroidal membrane protein that mediates iodide transport into thyroid follicular cells, NIS plays a key role in thyroid pathophysiology and allows very effective use of radioiodine for therapy of thyroid cancer. Most studies have demonstrated decreased NIS expression levels in thyroid carcinomas. Retinoic acide and demethylation as well as histone deacetylase inhibitors treatment, have been explored with the aim of stimulating NIS expression and optimizing therapeutic responsiveness to 131I in thyroid cancer. In addition, cloning and molecular analysis of the NIS gene offer the possibility of a novel cytoreductive gene therapy strategy based on targeted NIS gene transfer into thyroidal tumors.

参考文献/References:

1 Arturi F,Russo D,Schlumberger M,et al.Iodide symporter gene expression in human thyroid tumors[J].J Clin Endocrinol Metab,1998,83(7):2493-2496.
2 Park HJ,Kim JY,Park KY,et al.Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas[J].Thyroid,2000,10(3):211-217.
3 Min JJ,Chung JK,Lee YJ,et al.Relationship between expression of the sodium/iodide symporter and 131 I uptake in recurrent lesions of differentiated thyroid carcinoma[J].Eur J Nucl Med,2001,28(5):639-645.
4 Castro MR,Bergert ER,Goellner JR,et al.Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer:correlation with radioiodine uptake[J].J Clin Endocrinol Metab,2001,86(11):5627-5632.
5 Russo D,Manole D,Arturi F,et al.Absence of sodium/iodide sym-porter gene mutations in differentiated human thyroid carcinomas[J].Thyroid,2001,11(1):37-39.
6 Saito T,Endo T,Kawaguchi A,et al.Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas[J].J Clin Invest,1998,101(7):1296-1300.
7 Dohan 0,Baloch Z,Banrevi Z,et al.Predominant intracellular overexpression of the Na+/I- symporter (NIS)in a large sampling of thyroid cancer cases[J].J Clin Endocrinol Metab,2001,86(6):2697-2700.
8 Schmutzler C,Winzer R,Meissner-Weigl J,et al.Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells[J].Biochem Biophys Res Commun,1997,240(3):832-838.
9 Grünwald F,Menzel C,Bender H,et al.Redifferentiation therapy-induced radioiodine uptake in thyroid cancer[J].J Nucl Med,1998,39(11):1903-1906.
10 Simon D,Korber C,Krausch M,et al.Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer:final results of a pilot study[J].Eur J Nucl Med,2002,29(6):775-782.
11 Haugen BR,Larson LL,Pugazhenthi U,et al.Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids[J].J Clin Endocrinol Metab,2004,89(1):272-280.
12 Venkataraman GM,Yatin M,Marcinek R,et al.Restoration of iodide uptake in dedifferentiated thyroid carcinoma:Relationship to human Na+/I- symporter gene methylation status[J].J Clin Endocrinol Metab,1999,84(7):2449-2457.
13 Kitazono M,Robey R,Zhan Z,et al.Low concentrations of the his-tone deacetylase inhibitor,depsipeptide (FR901228),increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells[J].J Clin Endocrinol Metab,2001,86(7):3430-3435.
14 Zarnegar R,Brunaud L,Kanauchi H,et al.Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A,a histone deacetylase inhibitor[J].Surgery,2002,132(6):984-990.
15 Smit JW,Schröder-van der Elst JP,Karperien M,et al.Reestablishment of vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line[J].Thyroid,2000,10(11):939-943.
16 Smit JW,Schröder-Van der Elst JP,Karperien M,et al.Iodide kinetics and experimental 131I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line[J].J Clin Endocrinol Metab,2002,87(3):1247-1253.
17 Petrich T,Helmeke HJ,Meyer GJ,et al.Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter[J].Eur J Nucl Med Mol Imag,2002,29(7):842-854,
18 Dadachova E,Bouzahzah B,Zuckier LS,et al.Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)[J].Nucl Med Biol,2002,29(1):13-18.
19 Mandell RB,Mandell LZ,Link CJ.Radioisotope concentrator gene therapy using the sodium/iodide symporter gene[J].Cancer Res,1999,59(1):661-668.
20 Boland A,Magnon C,Filetti S,et al.Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers[J].Thyroid,2002,12(1):19-26.
21 Huang M,Batra RK,Kogai T,et al.Ectopic expression of the thy-roperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer[J].Cancer Gene Ther,2001,8(8):612-618.

相似文献/References:

[1]李雨,赵芳,蔡建明.切尔诺贝利核事故导致的人类甲状腺癌[J].国际放射医学核医学杂志,2004,28(2):86.
　LI Yu,ZHAO Fang,CAI Jian-ming.Thyroid carcinomas induced by Chernobyl nuclear accident[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):86.
[2]袁志斌.PET显像在内分泌肿瘤中的应用[J].国际放射医学核医学杂志,2003,27(5):208.
　YUAN Zhi-bin.The application of PET in endocrine tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(6):208.
[3]葛素娟.甲状腺癌术后131I治疗[J].国际放射医学核医学杂志,2002,26(4):163.
　GE Su-juan.131I therapy of thyroid cancer after surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(6):163.
[4]程刚.甲状腺癌的基因治疗[J].国际放射医学核医学杂志,2002,26(6):253.
　CHENG Gang.Gene therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(6):253.
[5]柳卫,张满达,王铁生.钠/碘同向转运体[J].国际放射医学核医学杂志,2001,25(2):49.
　LIU Wei.The sodium/iodide symporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):49.
[6]罗全勇.基因转染诱导核素靶向治疗的实验研究[J].国际放射医学核医学杂志,2001,25(2):60.
　LUO Quan-yong.Inducement of radionuclides targeting therapy by gene transfection[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):60.
[7]黄蕤.NIS基因转染肿瘤细胞介导131I治疗[J].国际放射医学核医学杂志,2001,25(5):204.
　HUANG Rui.Transfection of the Na+/I- symporter gene into tumors for radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):204.
[8]刘长安,贾廷珍.切尔诺贝利核事故受照人群的甲状腺效应[J].国际放射医学核医学杂志,1997,21(4):184.
[9]陈立波.钠/碘同向转运体与放射性碘治疗[J].国际放射医学核医学杂志,2001,25(6):258.
　CHEN Li-bo.The sodium/iodide symporter and radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):258.

备注/Memo

备注/Memo:
收稿日期:2004-04-21。
更新日期/Last Update: 1900-01-01